IN8bio, Inc. (INAB) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 21, 2025, reports on clinical trial data presented by IN8bio, Inc. at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The Company is an emerging growth company focused on developing DeltExTM Drug Resistant Immunotherapy (DRI) for newly diagnosed glioblastoma (GBM).
Key Clinical Metrics
The filing details results from an investigator-sponsored Phase 1 trial of INB-200 and a Company-sponsored Phase 2 trial of INB-400. No financial metrics (revenue, profit, cash flow, debt, or liquidity) are provided in this specific filing.
- Total Patients Treated: 17 patients received DeltEx DRI gamma-delta T cells; 14 received repeated doses (3 to 6).
- Control Group: 10 patients received only the standard-of-care (SOC) Stupp protocol.
- Median Progression-Free Survival (mPFS): 13.0 months for repeated DeltEx DRI doses vs. 6.6 months for SOC.
- Median Overall Survival (mOS): Not yet reached for DeltEx DRI group (16.4+ months as of October 31, 2025) vs. 11.0 months for SOC.
Material Changes and Outlook
The filing highlights a significant improvement in survival metrics for patients receiving repeated doses of the Company's therapy compared to the standard of care. Management commentary is limited to the presentation of these clinical results. No specific financial guidance, risks, or contingencies are detailed in this report beyond the inherent risks of clinical development.
Investor Verification Checklist
- Verify the full statistical analysis and confidence intervals for the reported mPFS and mOS data in the original SNO presentation materials.
- Confirm the specific inclusion/exclusion criteria for the 17 treated patients versus the 10 SOC patients to assess comparability.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor upcoming regulatory filings for any updates on the Phase 2 trial design or potential Phase 3 initiation timelines.